National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Biktarvy® for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.

 

NCPE Assessment Process Complete
Rapid review commissioned 30/04/2018
Rapid review completed 07/06/2018
Rapid Review outcome Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.